STRM.BIO is a biotechnology company developing a non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of genetic medicines.
Its megakaryocyte-derived vesicle (MV) platform focuses on non-viral gene delivery for hematological diseases and in vivo immune and hematopoietic cell engineering, enabling applications in gene editing, RNA therapeutics, and immune cell engineering.
Leadership & Board
Current Number of Employees17
Current LinkedIn Followers4,632
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$8M
Total Amount Raised$8M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$8M
Latest Funding Amount$8M
Latest Funding RoundSeed Round
Latest Funding RoundSeed Round
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
STRMBIO had 17 employees as of September 7, 2026. The number of employees decreased by 1 (5.56%) week-over-week.
17Latest Employee Count
1(-5.56%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
STRMBIO had 4,632 followers as of September 7, 2026. The number of followers increased by 4 (0.09%) week-over-week.
4,632Latest Followers Count
4(0.09%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.